UK markets closed

MRNA Jan 2025 90.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
43.55+13.25 (+43.73%)
As of 03:49PM EDT. Market open.
Full screen
Previous close30.30
Open42.30
Bid43.90
Ask44.75
Strike90.00
Expiry date2025-01-17
Day's range42.30 - 44.33
Contract rangeN/A
Volume15
Open interest570
  • Yahoo Finance Video

    Novo Nordisk slides while Moderna pops: Tale of two pharma stocks

    Pharmaceutical stocks Novo Nordisk (NVO) and Moderna (MRNA) are trending in opposite directions following their earnings reports. Despite topping Wall Street's profit expectations, Novo Nordisk shares are sinking as the company fell short of estimates for its popular GLP-1 weight-loss drug, Wegovy. Meanwhile, Moderna is on the rise even after reporting first quarter losses. Moderna's growth is largely due to an uptick in coronavirus boosters and an expansion into the Brazillian market. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl

  • Investor's Business Daily

    Moderna Breaks Out For The First Time In A Year After Covid Shot Wallops Sales Views

    Moderna stock broke out for the first time in a year Thursday after beating first-quarter expectations as its second potential approval looms.

  • Benzinga

    Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025 Formula, Stock Soars

    Thursday, Moderna Inc (NASDAQ:MRNA) reported a first-quarter EPS loss of $(3.07), down from an income of $(0.19), smaller than the consensus estimate loss of $(3.55). The company reported sales of $167 million, sharply below $1.9 billion a year ago due to evaporating COVID-19 vaccine sales, beating the consensus of $97.5 million. The company cut research and development expenses by 6% in the quarter, mainly due to the absence of upfront collaboration payments. Moderna added that clinical develop